ZA200601429B - Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof - Google Patents

Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof Download PDF

Info

Publication number: ZA200601429B
Authority: ZA; South Africa
Prior art keywords: synthesis; process according; formula; compound; perindopril
Prior art date: 2003-08-29

Application number

ZA200601429A

Other languages

English (en)

Inventor

Dubuffet Thierry

Lecouve Jean-Pierre

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-29

Filing date

2004-08-27

Publication date

2007-05-30

2004-08-27 Application filed by Servier Lab filed Critical Servier Lab

2007-05-30 Publication of ZA200601429B publication Critical patent/ZA200601429B/en

Links

230000015572 biosynthetic process Effects 0.000 title claims description 13
238000003786 synthesis reaction Methods 0.000 title claims description 13
238000000034 method Methods 0.000 title claims description 12
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims description 10
229960002582 perindopril Drugs 0.000 title claims description 10
150000003839 salts Chemical class 0.000 title claims description 5
150000001875 compounds Chemical class 0.000 claims description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
238000010511 deprotection reaction Methods 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
239000011707 mineral Substances 0.000 claims description 3
239000002904 solvent Substances 0.000 claims description 3
230000001476 alcoholic effect Effects 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
YERWBBMSDMSDKT-UHFFFAOYSA-N ethyl 2-oxopentanoate Chemical compound CCCC(=O)C(=O)OCC YERWBBMSDMSDKT-UHFFFAOYSA-N 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 2
238000005984 hydrogenation reaction Methods 0.000 claims 3
229910052799 carbon Inorganic materials 0.000 claims 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000002265 prevention Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
102000005862 Angiotensin II Human genes 0.000 description 1
101800000734 Angiotensin-1 Proteins 0.000 description 1
102400000344 Angiotensin-1 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
HDCVJBXIISZAHS-GUYCJALGSA-N benzyl (2s)-1-[(2s)-2-aminopropanoyl]-2,3,4,5,6,7-hexahydroindole-2-carboxylate Chemical compound O=C([C@H]1N(C2=C(CCCC2)C1)C(=O)[C@@H](N)C)OCC1=CC=CC=C1 HDCVJBXIISZAHS-GUYCJALGSA-N 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200601429A 2003-08-29 2004-08-27 Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof ZA200601429B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03292132A EP1380591B1 (de)	2003-08-29	2003-08-29	Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salzen

Publications (1)

Publication Number	Publication Date
ZA200601429B true ZA200601429B (en)	2007-05-30

Family

ID=29724624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200601429A ZA200601429B (en)	2003-08-29	2004-08-27	Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof

Country Status (17)

Country	Link
US (1)	US7534896B2 (de)
EP (1)	EP1380591B1 (de)
JP (1)	JP4331206B2 (de)
CN (1)	CN100383160C (de)
AR (1)	AR045516A1 (de)
AT (1)	ATE310012T1 (de)
AU (1)	AU2004270428B2 (de)
DE (1)	DE60302287T2 (de)
DK (1)	DK1380591T3 (de)
EA (1)	EA008668B1 (de)
ES (1)	ES2252633T3 (de)
MY (1)	MY136638A (de)
NZ (1)	NZ545336A (de)
PL (1)	PL211508B1 (de)
SI (1)	SI1380591T1 (de)
WO (1)	WO2005023842A1 (de)
ZA (1)	ZA200601429B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE306496T1 (de) *	2003-08-29	2005-10-15	Servier Lab	Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
SI1679072T1 (sl)	2005-01-06	2009-02-28	Ipca Lab Ltd	Postopek za sintezo derivatov (2S,3aS,7aS)-1-(S)-alanil-oktahidro-1H-indol-2-karboksilne kisline inuporaba v sintezi perindoprila
HUE025982T2 (en) *	2008-06-24	2016-05-30	Mylan Laboratories Ltd	New polymorphic forms of perindopril (L) -arginine and a process for their preparation
WO2016178591A2 (en)	2015-05-05	2016-11-10	Gene Predit, Sa	Genetic markers and treatment of male obesity
PH12018502155B1 (en)	2016-04-20	2024-03-27	Servier Lab	Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
JP6753699B2 (ja) *	2016-05-27	2020-09-09	ミネベアミツミ株式会社	転がり軸受

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1321471E (pt)	2003-03-12	2005-07-29	Servier Lab	Novo processo de sintese do perindopril e dos seus sais aceitaveis sob o ponto de vista farmaceutico
ATE280775T1 (de) *	2003-03-12	2004-11-15	Servier Lab	Verfahren zur synthese von (2s,3as,7as)-1-((s)-
ATE315043T1 (de) *	2003-06-30	2006-02-15	Servier Lab	Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
ATE338766T1 (de) *	2003-08-29	2006-09-15	Servier Lab	Verfahren für die synthese von perindopril und seiner pharmazeutisch annehmbaren salzen
ATE306496T1 (de) *	2003-08-29	2005-10-15	Servier Lab	Verfahren für die synthese von perindopril und seiner pharmazeutischen annehmbaren salzen
PT1420028E (pt) *	2003-11-19	2007-05-31	Servier Lab	Processo de síntese do perindopril e dos seus sais farmacêuticamente aceitáveis.

2003
- 2003-08-29 EP EP03292132A patent/EP1380591B1/de not_active Expired - Lifetime
- 2003-08-29 DK DK03292132T patent/DK1380591T3/da active
- 2003-08-29 ES ES03292132T patent/ES2252633T3/es not_active Expired - Lifetime
- 2003-08-29 DE DE60302287T patent/DE60302287T2/de not_active Expired - Lifetime
- 2003-08-29 SI SI200330124T patent/SI1380591T1/sl unknown
- 2003-08-29 AT AT03292132T patent/ATE310012T1/de active
2004
- 2004-08-26 MY MYPI20043495A patent/MY136638A/en unknown
- 2004-08-27 US US10/569,537 patent/US7534896B2/en not_active Expired - Fee Related
- 2004-08-27 PL PL379628A patent/PL211508B1/pl unknown
- 2004-08-27 EA EA200600454A patent/EA008668B1/ru not_active IP Right Cessation
- 2004-08-27 CN CNB2004800235355A patent/CN100383160C/zh not_active Expired - Fee Related
- 2004-08-27 NZ NZ545336A patent/NZ545336A/en not_active IP Right Cessation
- 2004-08-27 AU AU2004270428A patent/AU2004270428B2/en not_active Ceased
- 2004-08-27 ZA ZA200601429A patent/ZA200601429B/en unknown
- 2004-08-27 JP JP2006524395A patent/JP4331206B2/ja not_active Expired - Fee Related
- 2004-08-27 AR ARP040103079A patent/AR045516A1/es not_active Application Discontinuation
- 2004-08-27 WO PCT/FR2004/002197 patent/WO2005023842A1/fr not_active Ceased

Also Published As

Publication number	Publication date
DE60302287D1 (de)	2005-12-22
EA008668B1 (ru)	2007-06-29
EP1380591B1 (de)	2005-11-16
HK1096408A1 (en)	2007-06-01
US7534896B2 (en)	2009-05-19
MY136638A (en)	2008-11-28
EA200600454A1 (ru)	2006-08-25
ATE310012T1 (de)	2005-12-15
WO2005023842A1 (fr)	2005-03-17
DK1380591T3 (da)	2006-01-23
NZ545336A (en)	2009-03-31
AU2004270428A1 (en)	2005-03-17
ES2252633T3 (es)	2006-05-16
CN1835966A (zh)	2006-09-20
CN100383160C (zh)	2008-04-23
SI1380591T1 (sl)	2006-02-28
JP2007526902A (ja)	2007-09-20
US20070010572A1 (en)	2007-01-11
PL211508B1 (pl)	2012-05-31
JP4331206B2 (ja)	2009-09-16
DE60302287T2 (de)	2006-08-10
PL379628A1 (pl)	2006-10-30
AR045516A1 (es)	2005-11-02
EP1380591A1 (de)	2004-01-14
AU2004270428B2 (en)	2008-08-21

Publication	Publication Date	Title
BG65984B1 (bg)	2010-08-31	Метод за синтез на периндоприл и негови фармацевтично приемливи соли
US7223872B2 (en)	2007-05-29	Process for the synthesis of perindopril and its pharmaceutically acceptable salts
NZ544003A (en)	2009-03-31	Novel method of synthesising perindopril and pharmaceutically-acceptable salts thereof
US7183308B1 (en)	2007-02-27	Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
US7534896B2 (en)	2009-05-19	Process for the synthesis of perindopril and its pharmaceutically acceptable salts
US7279583B2 (en)	2007-10-09	Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
NZ544880A (en)	2009-03-31	Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
HK1097852B (en)	2008-06-06	Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
HK1096408B (en)	2008-11-28	Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
JP2007537996A (ja)	2007-12-27	（２Ｓ，３ａＳ，７ａＳ）−１−［（Ｓ）−アラニル］オクタヒドロ−１Ｈ−インドール−２−カルボン酸の誘導体を合成する方法、およびペリンドプリルの合成のためのその使用
HK1095840B (en)	2009-07-24	Method for the synthesis of derivatives of (2s,3as,7as)-1[(s)-alanyl]-octahydro-1h-indole-2-carboxylic acid and use thereof for the synthesis of perindopril